A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients — FACT  

Fibrillary Glomerulonephritis Clinical Trial

Official title: A Multicenter, Comparative Safety and Efficacy Study of ACTHar Gel Alone or in Combination With Oral Tacrolimus to Reduce Urinary Proteinuria in Patients With Idiopathic DNAJB9 Positive Fibrillary Glomerulopathy

Status Active, not recruiting

Clinical Trial Summary

A Multicenter, Comparative Safety and Efficacy Study of Acthar gel alone or in combination with oral Tacrolimus to reduce urinary proteinuria in patients with idiopathic DNAJB9 Positive Fibrillary glomerulopathy.

Clinical Trial Description

A Multicenter, Comparative Safety and Efficacy Study of Acthar gel alone or in combination with oral Tacrolimus to reduce urinary proteinuria in patients with idiopathic DNAJB9 Positive Fibrillary glomerulopathy. This study will be a multi-center, prospective, randomized, open-labeled intervention trial of 34 patients randomized to 52 weeks of ACTHar gel alone or Acthar gel plus oral Tacrolimus. ;

Related Conditions & MeSH terms

• Fibrillary Glomerulonephritis
• Glomerulonephritis
• Proteinuria

• NCT number: NCT05546047
• Study type: Interventional
• Source: NephroNet, Inc.
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: March 14, 2019
• Completion date: October 27, 2024